UroToday.com

@urotoday

Largest global online community of medical professionals & patients.TweetsCover:

San Francisco, CA
Vrijeme pridruživanja: veljača 2009.
16,8 tis. fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @urotoday

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @urotoday

  1. prije 15 sati

    -altered : clinical features and therapeutic outcomes to standard systemic therapies, PARP, and PD1 inhibitors presented by Emmanuel Antonarakis, MB BCh coverage by on UroToday.

    1 korisnik označava da mu se sviđa
    Poništi
  2. proslijedio/la je Tweet
    prije 15 sati

    Laurence Baskin, MD, Dylan Isaacson, MD, discusses imaging the developing human external and internal urogenital organs with light Sheet fluorescence microscopy. on

    1 proslijeđeni tweet 1 korisnik označava da mu se sviđa
    Poništi
  3. prije 17 sati

    Outcomes and perioperative complications of robotic pyelolithotomy with Michael Schulster, MD and . on UroToday >

    1 korisnik označava da mu se sviđa
    Poništi
  4. prije 17 sati

    Results and lessons learned from the Consensus Conference for Developing Countries. Fernando Maluf, MD discussion with . on UroToday >

    1 proslijeđeni tweet 1 korisnik označava da mu se sviđa
    Poništi
  5. prije 18 sati

    Risk factors of intravesical recurrence in patients with after radical nephroureterectomy. from of Rinaldetti et al. article in Clinical Genitourinary Cancer >

    2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa
    Poništi
  6. prije 19 sati

    Metastatic castration-sensitive : Abiraterone, Docetaxel, or... with Patrick Cotogno, MSPH, and . on UroToday >

    Poništi
  7. prije 20 sati

    Performance of PCA3 and TMPRSS2: ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study . article on UroToday >

    3 proslijeđena tweeta 7 korisnika označava da im se sviđa
    Poništi
  8. prije 22 sata

    Improving IMDC prognostic prediction through evaluation of initial site of metastasis in patients with mRCC. et. al. on UroToday >

    2 proslijeđena tweeta 3 korisnika označavaju da im se sviđa
    Poništi
  9. prije 23 sata

    2020 Genitourinary Cancers Symposium - February 13-15th. For conference summaries of live GU sessions written by urologists and oncologists delivered to your inbox now >

    2 korisnika označavaju da im se sviđa
    Poništi
  10. prije 23 sata

    Urine is not sterile: What the urobiome means for pelvic floor surgeons. Presentation by Alan Wolfe, PhD on urinary microbiota at . on UroToday >

    2 proslijeđena tweeta 8 korisnika označava da im se sviđa
    Poništi
  11. 3. velj

    Monitoring and Managing Toxicities in Patients with Metastatic Hormone-Sensitive . article by . on UroToday >

    2 korisnika označavaju da im se sviđa
    Poništi
  12. 2. velj

    "PI-RADS score predictive for detection of higher-grade cancer". : Outcomes of serial mpMRI and subsequent biopsy in men with low-risk prostate cancer managed with AS on UroToday.

    5 korisnika označava da im se sviđa
    Poništi
  13. 2. velj

    Optimizing bone health in . Fred Saad, MD, FRCS reviews osteoporosis, treatment-induced bone loss, and pharmacologic strategies to optimize throughout the disease spectrum on UroToday >

    Poništi
  14. 2. velj

    Efficacy & biomarker analysis of pts with adv. RCC with sarcomatoid histology: subgroup analysis from renal 101 presentations by . coverage by on UroToday > .

    9 proslijeđenih tweetova 9 korisnika označava da im se sviđa
    Poništi
  15. 2. velj

    Preparing your practice for the new era of theranostics by discussing the trial and questions to be considered regarding PSMA targeted therapies, on UroToday now >

    1 proslijeđeni tweet 3 korisnika označavaju da im se sviđa
    Poništi
  16. 1. velj

    Definition and overview of treatment options in . Howard Scher, MD discusses patients who never had detectable metastases on “conventional/ standard” imaging . on UroToday >

    1 proslijeđeni tweet
    Poništi
  17. 1. velj

    Efficacy and biomarker analysis of patients with adv. RCC with Sarcomatoid histology: subgroup analysis from Renal 101 of first-line avelumab + axitinib vs sunitinib discussion by . Coverage by

    9 proslijeđenih tweetova 18 korisnika označava da im se sviđa
    Poništi
  18. 1. velj

    Patient-reported outcomes from in patients with mCSPC discussion by . Written coverage by on UroToday >

    1 proslijeđeni tweet 7 korisnika označava da im se sviđa
    Poništi
  19. 1. velj

    Clinical implications of the trial cabazitaxel vs Abi or Enza in pts previously treated w/ docetaxel & had progression within 12 mths while receiving the alternative inhibitor.

    5 proslijeđenih tweetova 12 korisnika označava da im se sviđa
    Poništi
  20. 1. velj

    Supine PCNL (Ambulatory): Who? What? When? Why? How? presents on the revolution and the evolution of percutaneous renal surgery. on UroToday >

    1 proslijeđeni tweet 3 korisnika označavaju da im se sviđa
    Poništi

@urotoday još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·